journal cover

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

Neuro-oncology

Oct 31, 2014

Anna S BerghoffWolfgang Wick

Abstract

Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in several cancer types. We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-1, and PD-L1 and pyrosequencing for assessment of t...read more

Mentioned in this Paper

Glioblastoma Multiforme
Tumor Cells, Uncertain Whether Benign or Malignant
SNCA gene
Tissue Membrane
CD20 Expressing Cell Measurement
Immunohistochemistry
MS4A1 gene
Protein Methylation
Kaplan-Meier Estimate
Neoplasms
6
1
209
Paper Details
References
  • References50
  • Citations77
12345
  • References50
  • Citations77
12345...

Similar Papers Found In These Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Non-Small Cell Lung Cancer Recurrence

PTEN Tumour Suppressor

PTEN (phosphatase and tensin homologue deleted on chromosome 10) tumour suppressor is a PI (phosphoinositide) 3-phosphatase that can inhibit cellular proliferation, survival and growth by inactivating PI 3-kinase-dependent signalling. It also suppresses cellular motility through mechanisms that may be partially independent of phosphatase activity. PTEN is one of the most commonly lost tumour suppressors in human cancer, and its deregulation is also implicated in several other diseases.

Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) is a tumor that develops from astrocytes and oligodendrocytes. Here is the latest research on mechanisms that underlie GBM and associated therapeutic approaches.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

© 2020 Meta ULC. All rights reserved

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

Neuro-oncology

Oct 31, 2014

Anna S BerghoffWolfgang Wick

PMID: 25355681

DOI: 10.1093/neuonc/nou307

Abstract

Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in several cancer types. We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-1, and PD-L1 and pyrosequencing for assessment of t...read more

Mentioned in this Paper

Glioblastoma Multiforme
Tumor Cells, Uncertain Whether Benign or Malignant
SNCA gene
Tissue Membrane
CD20 Expressing Cell Measurement
Immunohistochemistry
MS4A1 gene
Protein Methylation
Kaplan-Meier Estimate
Neoplasms
6
1
209

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References50
  • Citations77
12345
  • References50
  • Citations77
12345...
/papers/programmed-death-ligand-1-expression-and-tumor-inf/25355681